Canada’s Drug Agency (CDA-AMC) recommends that Keytruda be reimbursed by public drug plans for the treatment of adult patients with
Immune checkpoint inhibitor–based therapies, especially dual immune checkpoint inhibitor regimens, are now frequently used as initial treatments for advanced or
Sexual dysfunction, including erectile dysfunction (ED) is a common problem for males starting in their early 40s and increases with
Canada’s Drug Agency (CDA-AMC) recommends that Enhertu be reimbursed by public drug plans for the second-line treatment of adult patients
People who receive home- and community-based services (HCBS) have diverse and unique needs that can be met with these services
Hepatitis B (HBV) infection is a major public health problem and cause of chronic liver disease.
